Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.38 |
| ▸ | CCR6 | P51684 | 3/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640382 | 1.00 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4DCCR6DPP4 | |
| SCHEMBL640380 | 1.00 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4DCCR6DPP4 | |
| SCHEMBL641122 | 1.00 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4DCCR6DPP4 | |
| SCHEMBL641123 | 1.00 | HCRTR1 (0.39) | HCRTR1HCRTR2KDM4DCCR6DPP4 | |
| SCHEMBL639757 | 0.96 | KDM4D (0.40) | HCRTR1HCRTR2KDM4DCCR6RORC | |
| SCHEMBL639755 | 0.96 | KDM4D (0.40) | HCRTR1HCRTR2KDM4DCCR6RORC | |
| SCHEMBL639756 | 0.96 | KDM4D (0.40) | HCRTR1HCRTR2KDM4DCCR6RORC | |
| SCHEMBL640260 | 0.92 | KMT2A (0.41) | HCRTR1HCRTR2KDM4DCCR6RORC | |
| SCHEMBL641755 | 0.87 | STS (0.40) | HCRTR1HCRTR2CCR6MMP1MMP9 | |
| SCHEMBL641757 | 0.87 | STS (0.40) | HCRTR1HCRTR2CCR6MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | HCRTR1 951/4885HCRTR2 641/4885KDM4D 4165/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | HCRTR1 951/4885HCRTR2 641/4885KDM4D 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.